{"organizations": [], "uuid": "1a72a938fa78e6a3b50fdf47a8acc84a2250c54b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-cellect-announces-opening-of-secon/brief-cellect-announces-opening-of-second-clinical-trial-site-and-approval-from-safety-board-for-dose-escalation-idUSASB0C0ZO", "country": "US", "domain_rank": 408, "title": "BRIEF-Cellect Announces Opening Of Second Clinical Trial Site And Approval From Safety Board (DSMB) For Dose Escalation", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-16T14:50:00.000+02:00", "replies_count": 0, "uuid": "1a72a938fa78e6a3b50fdf47a8acc84a2250c54b"}, "author": "", "url": "https://www.reuters.com/article/brief-cellect-announces-opening-of-secon/brief-cellect-announces-opening-of-second-clinical-trial-site-and-approval-from-safety-board-for-dose-escalation-idUSASB0C0ZO", "ord_in_thread": 0, "title": "BRIEF-Cellect Announces Opening Of Second Clinical Trial Site And Approval From Safety Board (DSMB) For Dose Escalation", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "safety board", "sentiment": "negative"}, {"name": "cellect biotechnology ltd", "sentiment": "none"}, {"name": "dsmb) for dose escalation reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 50 PM / Updated 8 minutes ago BRIEF-Cellect Announces Opening Of Second Clinical Trial Site And Approval From Safety Board (DSMB) For Dose Escalation Reuters Staff 1 Min Read \nJan 16 (Reuters) - Cellect Biotechnology Ltd: \n* CELLECT ANNOUNCES OPENING OF A SECOND CLINICAL TRIAL SITE AND APPROVAL FROM SAFETY BOARD (DSMB) FOR DOSE ESCALATION \n* CELLECT BIOTECHNOLOGY - ‍SIGNED AGREEMENT WITH HADASSAH MEDICAL CENTER TO CONDUCT CLINICAL TRIALS ON CANCER PATIENTS IN CO‘S ONGOING PHASE I/II STUDY​ \n* CELLECT BIOTECHNOLOGY -‍ GOT APPROVAL FROM DSMB TO ESCALATE APOGRAFT FASL PROTEIN DOSAGE TO 25 NG/ML, ENROLL 3 ADDITIONAL PATIENTS FOR CLINICAL TRIAL​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-16T14:50:00.000+02:00", "crawled": "2018-01-16T15:02:24.024+02:00", "highlightTitle": ""}